Worldwide more than 36 million people live with an HIV infection and thus with the expectation to develop AIDS sooner or later. Despite the available combined antiretroviral therapy, AIDS is far from being defeated. With an array of drugs, the therapy targets viral components and suppresses the replication of the virus and therewith in most cases the outbreak of the fatal AIDS disease. Due to the high mutation rate of the virus, new variations increasingly resistant against the existing drugs arise constantly. Additionally, many drugs cause severe side effects and cannot be permanently taken by a large number of patients. Therefore, despite the modern combined antiretroviral therapy annually around 22 000 HIV-infected alone in Western and Central Europe as well as USA die from the consequences of AIDS.
The ImmunoLogik GmbH develops an innovative lead candidate for the efficient and essential treatment of patients who have exploited all available means of the modern therapy, and who would die due to the unavoidable outbreak of AIDS. The lead candidate targets directly the components of the host cell, which are essential for the replication of HIV. The goal is to significantly reduce the risk of resistant virus variations.
• Co-inventor of ImmunoLogik’s lead candidate IML-106
• PhD thesis in molecular virology at the Friedrich-Alexander-University Erlangen-Nuremberg
• More than 12 years’ experience in virology with focus on HIV
• Former project leader of an independent HIV-1 research group at the Institute for Clinical and Molecular Virology in Erlangen
• Extensive research contributions in the development of novel antiretroviral strategies by deciphering molecular mechanisms, which regulate the functions of viral proteins and their cellular counterparts
• Scientific publications in leading international science journals
• Numerous active participations in renowned national and international virology congresses
• Co-founder of ImmunoLogik GmbH
• Doctoral thesis in biochemistry at the University of Leipzig
• Former group leader and staff scientist at the Department of Medical Immunology of the Medical Faculty of the Charité, Humboldt University Berlin
• Habilitation in “Experimental Virology” at the University of Hamburg
• 10 years at the National Institute of Allergy and Infectious Diseases in Bethesda, USA
• Since 2003 professor for virology at the Institute for Clinical and Molecular Virology in Erlangen
• 88 publications in renowned international science journals and more than 40 patent applications
• Substantially involved in the development of the blockbuster drug VELCADE® (bortezomib) by Millennium Pharmaceuticals Inc.
• More than 30 years of experience as:
• CEO Sandoz AG, managing director Novartis GmbH and Wander Pharma GmbH
• Committee member and chairman of the Federal Association of the Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie)
• Vice chairman of the Association of Research-based Pharmaceutical Companies (Verband Forschender Arzneimittelhersteller)
• 10 years board member of Forum MedTech Pharma
• Studies of business administration and law at University of Göttingen
• 25 years’ experience in international management consulting
• Certified Management Consultant (CMC) and member of Association of German Management Consultants (Bundesverband Deutscher Unternehmensberater)
• Board member Athenion AG & MetrioPharm AG
• Certified Management Consultant (CMC) and member of Association of German Management Consultants (Bundesverband Deutscher Unternehmensberater)
• Represents Athenion AG as anchor investor
• 15 years’ experience in pharmaceutical development and investment business
• Successful in the development of pharmaceutical projects for more than 15 years
• Enables ImmunoLogik to gain access to interdisciplinary expert teams from drug development, project and quality management, specialists in business development and patent law
• Preserves necessary corporate infrastructure for the ImmunoLogik for a reasonable price
The ImmunoLogik wishes all people involved in the project, partners and supporters a merry Christmas and a happy New Year 2019.
We are grateful for the support received and various engagement from countless companions in 2019. This gives us confidence to continue resolutely and with full vigor on the chosen path in future.
The ImmunoLogik and the university hospital Erlangen decided to continue their successful cooperation and agreed on an extension of the cooperation contract until September 2019.
The cooperation was and is still an important building block for the development of the innovative lead candidate IML-106 for the efficient and essential treatment of HIV patients who have exploited all available means of the modern therapy and would die due to the unavoidable outbreak of AIDS.
